Angela Riley, MD
Nephrology · Oxford, MSNPI 1568574457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Fresenius USA Marketing, Inc. accounts for 89.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $292 and has fallen 60.5% since, to $115 in 2025. That places this record below the midpoint for nephrology clinicians in MS, where the typical reported total is $1,460.
Across 65 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$1K
- Akebia Therapeutics Inc$45
- Nxstage Medical, Inc.$32
- AstraZeneca$23
- Inspire Medical Systems, Inc.$19
- Travere Therapeutics, Inc.$2
Across 776 payments — averaging $908.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$397K
- Akebia Therapeutics Inc$264K
- AstraZeneca$24K
- Alnylam Pharmaceuticals Inc.$20K
- CSL Behring$1K
What the payments were for
- Food & beverage$1,13498%
- Education$262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 59 | $1,040 |
| Akebia Therapeutics Inc | 2 | $45 |
| Nxstage Medical, Inc. | 1 | $32 |
| AstraZeneca | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $2 |
How this compares
$1,160 in reported general payments places this provider in the 45th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 96 | $209,469 |
| AuryxiaFerric Citrate | 45 | $86,884 |
| Sevelamer Carbonate | 235 | $34,262 |
| Lanthanum Carbonate | 15 | $14,233 |
| FarxigaDapagliflozin Propanediol | 11 | $6,299 |
| Calcium Acetate | 31 | $1,846 |
| Nifedipine ErNifedipine | 63 | $977 |
| Hydralazine Hcl | 82 | $896 |
| Metoprolol Succinate | 51 | $501 |
| Torsemide | 18 | $499 |
| Midodrine Hcl | 23 | $472 |
| Potassium Chloride | 47 | $450 |
| Pantoprazole Sodium | 51 | $436 |
| Carvedilol | 68 | $321 |
| Amlodipine Besylate | 84 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $1,040 | $209,46996 claims |
| Akebia Therapeutics IncAuryxia | $45 | $86,88445 claims |
| AstraZenecaFarxiga | $23 | $6,29911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Oxford
- Son LamOxford$6K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
- Francis PhillippiFlowood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.